

3.1 患者背景

3.1.1 患者背景一覧表

患者背景		血縁者間 骨髓移植	血縁者間末梢血 幹細胞移植	非血縁者間 骨髓移植	臍帯血移植	合計
患者数		3,069	4,494	8,492	7,007	23,062
性別	男性	1,729 (56.3%)	2,622 (58.3%)	5,069 (59.7%)	4,120 (58.8%)	13,540 (58.7%)
	女性	1,340 (43.7%)	1,872 (41.7%)	3,423 (40.3%)	2,887 (41.2%)	9,522 (41.3%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
年齢	0-17	1,028 (33.5%)	416 (9.3%)	1,109 (13.1%)	1,203 (17.2%)	3,756 (16.3%)
	18-55	1,580 (51.5%)	2,916 (64.9%)	4,948 (58.3%)	3,417 (48.8%)	12,861 (55.8%)
	56-	461 (15.0%)	1,162 (25.9%)	2,435 (28.7%)	2,386 (34.1%)	6,444 (27.9%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.0%)	1 (0.0%)
診断	AML	938 (30.6%)	1,871 (41.6%)	3,165 (37.3%)	3,108 (44.4%)	9,082 (39.4%)
	ALL	748 (24.4%)	781 (17.4%)	1,592 (18.8%)	1,232 (17.6%)	4,353 (18.9%)
	ATL	99 (3.2%)	187 (4.2%)	463 (5.5%)	265 (3.8%)	1,014 (4.4%)
	CML	71 (2.3%)	90 (2.0%)	215 (2.5%)	155 (2.2%)	531 (2.3%)
	MDS	281 (9.2%)	360 (8.0%)	989 (11.7%)	653 (9.3%)	2,283 (9.9%)
	NHL	238 (7.8%)	648 (14.4%)	854 (10.1%)	718 (10.3%)	2,458 (10.7%)
	固形腫瘍	68 (2.2%)	56 (1.3%)	13 (0.2%)	151 (2.2%)	288 (1.2%)
	その他	626 (20.4%)	501 (11.2%)	1,201 (14.1%)	725 (10.3%)	3,053 (13.2%)
移植時病期	CR	1,439 (46.9%)	1,785 (39.7%)	4,314 (50.8%)	2,732 (39.0%)	10,270 (44.5%)
	Non-CR	1,067 (34.8%)	2,444 (54.4%)	3,422 (40.3%)	3,749 (53.5%)	10,682 (46.3%)
	その他	483 (15.7%)	162 (3.6%)	620 (7.3%)	399 (5.7%)	1,664 (7.2%)
	不明・未記載	80 (2.6%)	103 (2.3%)	136 (1.6%)	127 (1.8%)	446 (1.9%)
BU剤型	BU(経静脈)を含むレジメン	702 (93.9%)	1,469 (90.3%)	2,743 (92.0%)	1,672 (93.9%)	6,586 (92.3%)
	BU(経口)を含むレジメン	46 (6.2%)	157 (9.7%)	240 (8.1%)	109 (6.1%)	552 (7.7%)
前治療レジメン	BU(経静脈)+CY±other	272 (12.9%)	367 (11.7%)	809 (11.6%)	244 (4.3%)	1,692 (9.4%)
	CY+TBI±other	1,026 (48.8%)	1,046 (33.3%)	2,809 (40.2%)	1,821 (31.8%)	6,702 (37.3%)
	BU(経静脈)+FL±other	371 (17.6%)	1,040 (33.1%)	1,872 (26.8%)	1,340 (23.4%)	4,623 (25.7%)
	FL+TBI±other	434 (20.6%)	689 (21.9%)	1,507 (21.5%)	2,329 (40.6%)	4,959 (27.6%)
GVHD予防薬	MTX+CyA	1,774 (57.8%)	2,061 (45.9%)	1,216 (14.3%)	1,545 (22.1%)	6,596 (28.6%)
	MTX+FK506	845 (27.5%)	951 (21.2%)	6,697 (78.9%)	2,497 (35.6%)	10,990 (47.7%)
	その他	450 (14.7%)	1,482 (33.0%)	579 (6.8%)	2,965 (42.3%)	5,476 (23.7%)

* 生存が不明の症例(49例)と最終生死確認日が不明の症例(12例)を以後の解析から除いた。

3.1.2 略語一覧

略語		
ARDS	Acute respiratory distress syndrome	急性呼吸促迫症候群
BU	Busulfan	ブスルファン
CY	Cyclophosphamide	シクロホスファミド
CyA	Cyclosporin A	シクロスポリンA
FK506	Tacrolimus	タクロリムス
FL	Fludarabine phosphate	フルダラビン
GVHD	Graft versus host disease	移植片対宿主病
iv	Intravenous	経静脈
MTX	Methotrexate	メトトレキサート
PTLD	Post-transplantation lymphoproliferative disorder	移植後リンパ増殖性疾患
SD	Standard deviation	標準偏差
TBI	Total body irradiation	全身放射線照射
TMA	Thrombotic microangiopathy	血栓性微小血管障害
VOD	Veno-occlusive disease	肝中心静脈閉塞症

* その他の略語は、移植アウトカムの解析の略語一覧にあります。